I'rom Group Co., Ltd. (2372.T)

Ascletis Announces 3CLpro Inhibitor ASC11 Demonstrated Potential to be Effective Treatment for COVID-19

Ascletis Pharma Inc. (HKEX: 1672) today announces that its oral small molecule drug candidate ASC11, a 3-chymotrypsin like protease (3CLpro) inhibitor, demonstrated potential to be effective treatment for COVID-19.